

# Genetic Variation at the *ADAMTS7* Locus is Associated With Reduced Severity of Coronary Artery Disease

Kenneth Chan, MRCP; Xiangyuan Pu, MD, PhD; Pratik Sandesara, MD; Robin N. Poston, MD, FRCPath; Iain A. Simpson, MD; Arshed A. Quyyumi, MD;\* Shu Ye, MD, PhD, FRCPath;\* Riyaz S. Patel, MD\*

**Background**—Genome-wide association studies identified *ADAMTS7* as a risk locus for coronary artery disease (CAD). Functional studies suggest that *ADAMTS7* may promote cellular processes in atherosclerosis. We sought to examine the association between genetic variation at *ADAMTS7* and measures of atherosclerosis using histological, angiographic, and clinical outcomes data.

**Methods and Results**—The lead CAD-associated single-nucleotide polymorphism rs3825807 at the *ADAMTS7* locus was genotyped. The G allele (reduced *ADAMTS7* function) was associated with a smaller fibrous cap ( $P=0.017$ ) and a smaller percentage area of  $\alpha$ -actin (smooth muscle cell marker) in the intima ( $P=0.017$ ), but was not associated with calcification or plaque thickness, following ex vivo immunohistochemistry analysis of human coronary plaques ( $n=50$ ; mean age  $72.2\pm 11.3$ ). In two independent cohorts (Southampton Atherosclerosis Study [ $n=1359$ ; mean age  $62.5\pm 10.3$ ; 70.1% men] and the Emory Cardiovascular Biobank [EmCAB;  $n=2684$ ; mean age  $63.8\pm 11.3$ ; 68.7% men]), the G allele was associated with 16% to 19% lower odds of obstructive CAD (Southampton Atherosclerosis Study: odds ratio, 0.81; 95% confidence interval, 0.67–0.98; EmCAB: odds ratio, 0.84; 95% confidence interval, 0.75–0.95) with similar effects for multivessel, left anterior descending, and proximal CAD. Furthermore, each copy of the G allele was associated with lower angiographic severity Gensini score (Southampton Atherosclerosis Study,  $P=0.026$ ; EmCAB,  $P<0.001$ ), lower Sullivan Extent score (Southampton Atherosclerosis Study,  $P=0.029$ ; EmCAB,  $P<0.001$ ), and a 23% lower risk of incident revascularization procedures (EmCAB: hazard ratio, 0.76; 95% confidence interval, 0.59–0.98). There were no associations with all-cause mortality or incident myocardial infarction.

**Conclusions**—Genetic variation at the *ADAMTS7* locus is associated with several complementary CAD phenotypes, supporting the emerging role of *ADAMTS7* in atherosclerosis and may represent a potential drug target. (*J Am Heart Assoc.* 2017;6:e006928. DOI: 10.1161/JAHA.117.006928.)

**Key Words:** angiography • atherogenesis • coronary artery disease • genetic association

Genome-wide association studies have revealed a robust association between genetic variation in the *ADAMTS7* (a disintegrin and metalloprotease with thrombospondin motif 7) gene on chromosome 15q25 and clinical phenotypes of coronary artery disease (CAD).<sup>1–3</sup> One of the lead single nucleotide polymorphisms (SNPs), rs3825807, is an adenine

(A) to guanine (G) substitution located in exon 4 of the *ADAMTS7* gene, with the G allele conferring a reduced risk of CAD,<sup>1–3</sup> and is found to be in linkage disequilibrium with other SNPs such as rs1994016<sup>2</sup> and rs7178051<sup>4</sup> commonly studied at the *ADAMTS7* loci. This nonsynonymous SNP leads to an amino acid change in the prodomain of the

From the Institute of Cardiovascular Sciences, University College London, London, United Kingdom (K.C., R.S.P.); Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, United Kingdom (K.C.); William Harvey Research Institute, Queen Mary University of London, United Kingdom (X.P., R.N.P.); Department of Medicine, Emory University School of Medicine, Atlanta, GA (P.S., A.A.Q.); Wessex Regional Cardiac Unit, Southampton University Hospital, Southampton, United Kingdom (I.A.S.); Department of Cardiovascular Sciences, University of Leicester, United Kingdom (S.Y.); Shantou University Medical College, Shantou, China (S.Y.); Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (R.S.P.).

Accompanying Tables S1 through S3 and Figure S1 are available at <http://jaha.ahajournals.org/content/6/11/e006928/DC1/embed/inline-supplementary-material-1.pdf>

\*Dr Quyyumi, Dr Ye and Dr Patel are joint last authors.

**Correspondence to:** Shu Ye, MD, PhD, FRCPath, Department of Cardiovascular Sciences, University of Leicester, Leicester LE3 9QP, United Kingdom. E-mail: sy127@le.ac.uk

Received June 15, 2017; accepted October 3, 2017.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

## Clinical Perspective

### What Is New?

- Variation in the ADAMTS7 gene has been associated with risk of coronary artery disease; however, its pathological and clinical consequences have yet to be determined.
- We found that a genetic variant associated with reduced function of ADAMTS7 is associated with less severe histological features of human atherosclerotic plaques, lower angiographic coronary artery disease severity in 2 independent cohorts, and lower risk of incident revascularization during follow-up.

### What Are the Clinical Implications?

- These findings are strongly consistent with the hypothesis that ADAMTS7 activity promotes atherosclerosis and therefore may represent a potential pathway for drug targeting.

ADAMTS7 protein, a metalloproteinase that plays a role in proteolysis and degradation of extracellular matrix in connective tissues.<sup>5</sup> Functional studies have revealed that this substitution affects maturation of ADAMTS7, resulting in reduced vascular smooth muscle cell migration.<sup>6</sup> Furthermore, in vivo animal studies show that *ADAMTS7* deficiency confers reduced atherosclerotic lesion formation and neointima thickening.<sup>7,8</sup>

These data therefore suggest an important role of normally functioning *ADAMTS7* in driving atherosclerosis and plaque development. We sought to further explore this hypothesis by examining whether genetic variation in *ADAMTS7* (and therefore reduced functional activity of the gene product) would be associated with lower measures of quantifiable atherosclerosis (in vivo and ex vivo) and clinically relevant outcomes.

## Methods

### Immunohistochemical Analysis of Ex Vivo Human Coronary Atherosclerotic Plaques

Human coronary arteries were obtained from authorized hospital postmortems for research purposes (n=50). DNA was extracted from tissues using the Wizard Genomic DNA purification kit (Promega).<sup>6</sup> Formaldehyde-fixed paraffin-embedded sections were deparaffinized, rehydrated, and incubated in sodium citrate for antigen retrieval. The sections were then double stained with anti-human smooth muscle  $\alpha$ -actin antibody (Sigma A5691) and anti-human ADAMTS7 antibody (Abcam, ab28557). Morphology of the section was determined by one investigator (K.C.) in accordance with

standard American Heart Association classification.<sup>9</sup> These were independently verified by an expert pathologist (R.N.P.) who was blinded to the findings, with complete agreement. For American Heart Association type V or VI classified plaques (fibroatheromatous), the intima and fibrous cap thicknesses were measured in the most representative area on a standardized scale and power field. The percentage area of positive  $\alpha$ -actin stain in the intima was calculated in both fibroatheromatous and fibrous plaques. Calcification of the atherosclerotic plaque was assessed as a binary measure—presence or absence—and by semiquantitative assessment on a scale of 0 to 3. All measurements were performed using Image-Pro 7.0.<sup>6</sup>

### Southampton Atherosclerosis Study

Consecutive white patients undergoing interventional or diagnostic coronary angiography were recruited in the Wessex Cardiothoracic Unit of the Southampton General Hospital from 1999 to 2002 as part of the SAS (Southampton Atherosclerosis Study).<sup>10</sup> The study was approved by the local research ethics committee, and all participants provided written consent. Demographic and clinical data were recorded including age, sex, weight, height, occupation, smoking habit, and number of cigarettes smoked per day by each smoker, the presence or absence of hyperlipidemia (defined as cholesterol >5.2 mmol/L and/or triglyceride >3 mmol/L), current medications particularly the use of statins and fibrates, hypertension (defined as diastolic blood pressure >95 mm Hg and/or systolic blood pressure >160 mm Hg), type 1 or type 2 diabetes mellitus, previous myocardial infarction (MI), and coronary heart disease in first-degree relatives younger than 65 years. DNA was extracted from peripheral blood samples using the “salting out” method.<sup>11</sup> ADAMTS7 rs3825807 was genotyped as part of the CARDIoGRAM project using the Sequenom platform.<sup>3</sup>

### Emory Cardiovascular Biobank

The Emory Cardiovascular Biobank (EmCAB) consists of 3600 consecutive patients aged 18 to 90 years, enrolled before undergoing elective or emergency cardiac catheterization across 3 Emory Healthcare sites in Atlanta between 2003 and 2009. The study was approved by the institutional review board of Emory University, Atlanta, GA, and all participants provided written informed consent. Patients were excluded if they had a history of heart transplantation. Full details of the cohort have been previously published.<sup>12</sup> Demographic characteristics; risk factors such as hypertension, dyslipidemia, and diabetes mellitus; and medication usage were recorded. Laboratory data were collected at the time of enrollment. Genotyping of SNPs including rs3825807 was performed at

deCODE genetics in Reykjavik, Iceland, using the Centaurus (Nanogen) Platform.<sup>12</sup>

## Coronary Angiography Evaluation

Coronary angiograms were systematically characterized by a consultant cardiologist in SAS. In EmCAB, angiograms were reported by 2 independent observers with good interobserver agreement and intraclass correlation coefficient of 0.88 (95% confidence interval [CI], 0.74–0.95).<sup>13</sup> Observers in both studies were blinded to genotype. The angiogram reports were then characterized for several anatomic and morphological criteria: (1) number of major epicardial vessels with >50% stenosis, where multivessel disease was defined as  $\geq 2$  vessels involvement; (2) anatomical location of the lesions using a 17-segment modified American Heart Association model<sup>14</sup>; and (3) the percentage diameter stenosis for each lesion graded into <25%, 26% to 50%, 51% to 74%, 75% to 94%, 95% to 99%, and 100% stenosis. Proximal disease was defined as lesions located in left main, proximal left anterior descending (LAD), proximal right coronary artery, and proximal left circumflex arteries.

A semiquantitative scoring system was used to grade the angiographic burden of CAD. The Gensini score is a nonlinear scale weighting lesions by prognostic significance, using location, ranging from 0.5 to 5.0, and degree of stenosis (<25%=2, 26–50%=4, 51–75%=8, 76–90%=16, 91–99%=32, and 100%=64); thus, left main and severe proximal lesions confer higher scores.<sup>15</sup> The Sullivan Extent score quantifies the proportional surface area of the coronary tree affected by atheroma, with the right coronary artery divided into 4 segments (25% per segment) and the LAD and left circumflex each divided into 3 segments (33% per segment).<sup>16</sup>

In both cohorts, only native vessel disease was scored. Stented segments were counted as diseased (>75%), while lesions or stents within arterial or venous grafts were not included.

## Incident Outcomes

Outcome data were available for the EmCAB cohort only. Patients were followed prospectively for determination of incident all-cause mortality (defined as death from any cause), incident nonfatal MI (defined using standard criteria for MI), and incident coronary artery revascularization (defined as native vessel revascularization with stenting or first coronary artery bypass grafting). Follow-up was performed by personnel blinded to genotype data through telephone interview, chart review, and linkage with the Social Security Death Index and State records. Medical records were accessed or requested to validate all self-reported events. Definitions

and details about follow-up and outcome ascertainment have been previously published.<sup>17</sup>

## Statistical Analysis

Continuous variables are presented as means (SDs) and categorical variables as proportions (percentages) with 1-way analysis of variance and  $\chi^2$  tests used to determine differences by genotype. Variables were tested for normality with Kolmogorov-Smirnov statistics and (+1 natural log) transformed where appropriate for parametric analyses and reverse transformed for interpretation of the effect estimate. Non-normally distributed variables were tested using appropriate nonparametric tests (Kruskal–Wallis). Haploview 4.0 (Broad Institute) was used to compute Hardy–Weinberg equilibrium and minor allele frequency for rs3825807. Power calculations were performed using G-Power package 3.1 (Heinrich-Heine-Universität Düsseldorf).

Logistic and linear regression models were constructed to test the additive effect of the rs3825807 SNP on CAD phenotypes including severity and extent, with the SNP coded as 0, 1, and 2, based on the number of minor alleles (G). Analyses were repeated after adjustment for traditional risk factors for CAD including age, sex, smoking status, diabetes mellitus, and hypertension.

We also conducted a meta-analysis of the summary estimates for the genotype–CAD association analysis from each cohort under a random-effects model. We calculated pooled statistics as odds ratios (ORs) with 95% CIs and overall  $z$  statistics. Cochran's  $Q$ ,  $\tau^2$ , and  $I^2$  index were used to assess heterogeneity between the 2 cohorts.

Outcome and survival data were analyzed using Cox proportional hazards regression models adjusted for age and sex, and further adjusted for other risk factors including smoking status, diabetes mellitus, and hypertension. Schoenfeld residuals were examined to check for violation of the proportional hazards assumption. Patients with heart transplants or coronary bypass grafting at baseline were excluded from the outcome analysis. A 2-tailed  $P < 0.05$  was considered significant. Statistical analyses were performed using SPSS version 18.0 (SPSS Inc).

## Results

### ADAMTS7 Association With Atherosclerotic Plaque Characteristics

Examining all 50 ex vivo human coronary atherosclerotic plaques together (mean age of patients  $72.2 \pm 11.3$  years, 47.6% men, all white), there was no statistically significant association between whole intima or media thickness with the G allele of the ADAMTS7 SNP (Table 1).

**Table 1.** Ex Vivo Coronary Atherosclerotic Plaque Characteristics by ADAMTS7 rs3825807 Genotype

All Coronary Plaques (n=50)	ADAMTS7 Genotype			$\beta$ (SE)	P Value
	AA (n=22)	AG (n=17)	GG (n=11)		
Whole intima thickness	699.4 (66.8)	793.5 (83.3)	667.8 (75.9)	17.3 (62.6)	0.54
Media thickness	134.6 (13.9)	156.4 (14.9)	167.7 (25.7)	17.1 (12.2)	0.38
AHA Class V or VI Plaques (n=28)	AA (n=14)	AG (n=9)	GG (n=5)		
Intima thickness	741.4 (69.4)	712.6 (88.6)	615.8 (67.8)	-23.6 (63.1)	0.35
Fibrous cap thickness	329.4 (51.4)	217.0 (36.1)	157.7 (8.8)	-88.8 (33.9)	0.017
Fibrous cap:intima thickness ratio	0.47 (0.06)	0.33 (0.06)	0.24 (0.04)	-0.11 (0.05)	0.039
Percent area $\alpha$ -actin stain in intima	36.0 (4.51)	29.2 (4.51)	17.0 (1.64)	-9.1 (3.5)	0.017
Calcification (binary), %	53.3	26.7	20		0.71
Calcification (quantitative)	1.46 (0.37)	1.00 (0.44)	1.40 (0.40)	-0.09 (0.31)	0.78


Coronary plaque features for the 50 ex vivo samples, presented by genotype of rs3825807 single nucleotide polymorphism. Intima, media, and fibrous cap thicknesses were measured in a.u. and expressed as mean (SEM). Characteristics are also shown for the subset of plaques falling into American Heart Association (AHA) class V or VI fibroatheroma and suitable for further characterization. Calcification was characterized as presence or absence (binary) or graded on a scale of 0 to 3 depending on burden of calcification (quantitative).

However, among the 28 plaque samples deemed to be fibroatheromatous according to American Heart Association criteria and suitable for further plaque characterization, there was a significant association between the rs3825807 G allele and reduced fibrous cap thickness ( $\beta -88.8 \pm 33.9$ ,  $P=0.017$ ), reduced fibrous cap-to-intima thickness ( $\beta -0.11 \pm 0.05$ ,  $P=0.039$ ), and a lower percentage area  $\alpha$ -actin in intima ( $\beta -0.08 \pm 0.03$ ,  $P=0.029$ ) under an additive genetic model

(Table 1 and Figure 1). There were no associations between the SNP and intima thickness or the extent of plaque calcification.

### ADAMTS7 Association With CAD

A total of 1359 white patients from SAS and 2684 white patients from EmCAB were genotyped for the ADAMTS7 SNP



**Figure 1.** Associations between human atherosclerotic plaque morphology and ADAMTS7 genotypes. A, Intima thickness, (B) fibrous cap thickness, (C) fibrous cap:intima thickness, (D) percentage  $\alpha$ -actin in intima. \* denotes  $p < 0.05$

rs3825807 and included in the analysis. Baseline patient characteristics for both cohorts are presented in Table 2. The mean age and proportion of men were similar in both SAS (62.8 [10.2] years and 70%) and EmCAB (63.8 [11.1] years and 68%) cohorts. However, there were some differences, including more smokers and fewer patients with diabetes mellitus in the SAS cohort (70% and 12%, respectively) compared with in the EmCAB cohort (60% and 30%, respectively). Significant (>50% stenosis) angiographic CAD was recorded in 79.2% of patients in SAS and 63.7% of patients in EmCAB, with the remainder having normal or nonobstructive disease. The observed genotype frequencies were consistent with Hardy–Weinberg equilibrium, and the minor allele frequency for rs3825807 was 0.43 for both cohorts, similar to previously published reports.<sup>1</sup>

The G allele of the ADAMTS7 SNP was associated with a protective effect on CAD in both cohorts, with a 16% to 19% lower odds of disease per allele after adjustment for age and sex (SAS: OR, 0.81 [95% CI, 0.67–0.98]; EmCAB: OR, 0.84 [95% CI, 0.75–0.95]). These estimates persisted after adjustment for further CAD risk factors. Consistent with prior reports, there was no significant association between the G allele and MI (SAS: OR, 1.01 [95% CI, 0.86–1.18]; EmCAB: OR, 0.85 [95% CI, 0.70–1.02]).

Similarly, we found that in both cohorts, the G allele was modestly associated with lower odds of multiple-vessel

disease (SAS: OR, 0.86 [95% CI, 0.74–1.00]; EmCAB: 0.81 [95% CI, 0.72–0.92]), as well as LAD disease (SAS: OR, 0.84 [95% CI, 0.72–0.98]; EmCAB: OR, 0.80 [95% CI, 0.71–0.89]) in both cohorts, and with proximal disease in EmCAB (Table 3).

Combining data for both cohorts through meta-analysis revealed that the G allele conferred a pooled OR of 0.84 (95% CI, 0.77–0.93) for obstructive CAD, 0.85 (95% CI, 0.78–0.93) for multivessel disease, 0.83 (95% CI, 0.76–0.91) for LAD disease, and 0.84 (95% CI, 0.76–0.93) for proximal disease (Figure S1). There was no significant heterogeneity  $\tau^2$  and  $I^2=0\%$  between the cohorts for the pooled analyses.

In addition, we identified an association between the G allele of the ADAMTS7 SNP and semiquantitative angiographic scores. In both cohorts, there was an  $\approx 5$ -point reduction in median Gensini score and a 10-point reduction in median Sullivan score between those with 2 copies of the G allele compared with those with none. Clinically, this difference can be interpreted as equivalent to, for example, a 50% discrete lesion in the proximal LAD (Gensini score=5) or detectable atheroma affecting half of the right coronary artery (Sullivan score=10). After adjustment for age and sex, the Gensini score was lower for each copy of the G allele in both SAS ( $P=0.026$ ) and EmoryCAB ( $P<0.001$ ), while Sullivan Extent score was also similarly lower in both cohorts (SAS  $P=0.029$ , EmCAB  $P<0.001$ ). These associations persisted after adjustment for further risk factors (Table 4).

**Table 2.** Patient Characteristics by ADAMTS7 rs3825807 Genotype

Patient Characteristics	Total	SAS			P Value	Total	EmCAB			P Value
		ADAMTS7 Genotype					ADAMTS7 Genotype			
		AA	AG	GG			AA	AG	GG	
No.	1359	472	595	292		2684	858	1336	490	
Age, y	62.5 (10.3)	62.2 (10.5)	62.8 (10.2)	62.2 (10.2)	0.63	63.8 (11.4)	63.9 (11.1)	64.0 (11.5)	63.3 (11.6)	0.56
Men, %	70.1	67.8	71.3	71.2	0.42	67.7	66.0	67.7	71.1	0.15
Body mass index, kg/m <sup>2</sup>	27.6 (4.4)	27.8 (4.4)	27.5 (4.4)	27.5 (4.4)	0.41	29.4 (6.1)	29.6 (6.2)	29.4 (6.2)	29.0 (5.8)	0.32
Diabetes mellitus, %	11.8	13.9	11.1	9.6	0.17	30.2	30.2	30.2	29.9	0.99
Hypertension, %	42.6	40.9	44.8	40.6	0.36	68.3	68.0	68.5	68.4	0.97
Hypercholesterolemia, %	79.2	82.2	78.0	77.1	0.14	70.0	70.7	69.1	71.3	0.59
Smoker, %	72.3	74.3	70.6	72.5	0.41	60.5	58.5	61.4	61.3	0.37
Statin use, %	49.1	45.1	51.4	50.7	0.10	24.9	24.3	25.3	24.5	0.86
Prior myocardial infarction, %	38.4	37.2	38.8	39.5	0.83	33.7	33.0	33.6	34.9	0.77
Normal coronaries, %	20.8	19.7	19.2	26.0	0.04	27.7	23.4	28.9	32.4	0.001
Angiographic CAD >50%, %	79.2	78.5	80.4	72.8	0.05	63.7	67.7	63.2	59.4	0.02

Data are presented as mean (SD) or percentage unless indicated by rs3825807 genotype for each study. CAD indicates coronary artery disease; EmCAB, Emory Cardiovascular Biobank; SAS, Southampton Atherosclerosis Study.



**Table 3.** Association Between Genetic Variation at ADAMTS7 (rs3825807) and Binary CAD Phenotypes

	OR (95% CI)*	Adjusted OR (95% CI)†
<b>Obstructive CAD</b>		
SAS	0.81 (0.67–0.98)	0.82 (0.67–0.99)
EmCAB	0.84 (0.75–0.95)	0.84 (0.74–0.95)
<b>Multivessel disease</b>		
SAS	0.86 (0.74–1.00)	0.87 (0.74–1.02)
EmCAB	0.81 (0.72–0.92)	0.82 (0.73–0.93)
<b>LAD disease</b>		
SAS	0.84 (0.72–0.98)	0.84 (0.71–0.98)
EmCAB	0.80 (0.71–0.89)	0.81 (0.72–0.91)
<b>Proximal disease</b>		
SAS	0.92 (0.75–1.13)	0.86 (0.69–1.07)
EmCAB	0.80 (0.72–0.90)	0.80 (0.71–0.90)

Odds ratio (OR) with 95% confidence interval (CI) derived for association between the G allele of rs3825807 and obstructive coronary artery disease (CAD) vs no CAD, multivessel disease vs single-vessel disease; left anterior descending (LAD) disease vs non-LAD disease, and proximal disease vs distal disease. EmCAB indicates Emory Cardiovascular Biobank; SAS, Southampton Atherosclerosis Study.

\*Adjusted for age and sex only.

†Adjusted for age, sex, smoking status, hypertension, and diabetes mellitus.

### Effect of ADAMTS7 on Cardiovascular Outcomes

Within the EmCAB cohort, after excluding those with prior coronary artery bypass grafting or heart transplants, 1929 patients with available follow-up data were included in the outcome analysis, with a median follow-up of  $3.0 \pm 2.3$  years. During this time, there were 184 (9.5%) all-cause deaths, 68 (3.5%) MI events, and 114 (5.9%) revascularization procedures. Cox regression analysis adjusted for traditional risk factors showed that there was no significant association for all-cause mortality (hazard ratio, 1.13; 95% CI, 0.94–1.38) or MI (hazard ratio, 0.85; 95% CI, 0.61–1.18) during the follow-

up period (Table 5). However, each additional G allele conferred a significantly lower risk of incident native vessel revascularization (hazard ratio, 0.76; 95% CI, 0.59–0.98) (Figure 2).

### Discussion

In this study, using (1) histological samples, (2) coronary angiographic phenotypes, and (3) clinical outcomes data, we demonstrate that a nonsynonymous SNP resulting in loss of function of ADAMTS7 is associated with reduced CAD burden. Collectively, our findings provide further support for the emerging role of this protease in promoting atherosclerosis.

Early genome-wide association studies first identified variants in the ADAMTS7 gene as associating with prevalent CAD and MI. In an important analysis, Reilly et al<sup>2</sup> identified this variant as associating with CAD but not MI, suggesting that the gene primarily drives atherosclerosis as its mechanism of risk. The adenine (A) to guanine (G) substitution of rs3825807 results in a serine-to-proline substitution in the prodomain of ADAMTS7,<sup>6</sup> and functional studies using cultured vascular smooth muscle cell model have revealed that this affects ADAMTS7 function not by influencing its expression but rather its maturation and thrombospondin-5 cleavage.<sup>6</sup> Recent in vivo studies using ADAMTS7-null knockout mouse models have shown that ADAMTS7<sup>-/-</sup> mice have less significant neointima thickening, likely through reduced vascular smooth muscle cell migration.<sup>8</sup> Normally functioning ADAMTS7 might also impair re-endothelialization by degrading thrombospondin-1, thereby inhibiting endothelial cell proliferation and migration.<sup>18</sup> These results thus indicate that ADAMTS7 may ordinarily promote atherosclerosis while impairment of this protein could halt the atherosclerotic process. However, this has not yet been assessed with detailed in vivo or ex vivo measures of atherosclerosis in humans.

**Table 4.** Association Between Genetic Variation at ADAMTS7 (rs3825807) and Angiographic CAD Scores

Angiographic Scores	ADAMTS7 Genotype			$\beta$ (SE)	P Value*	P Value†
	AA	AG	GG			
<b>Gensini</b>						
SAS	26.3 (7–57)	28 (7–57)	20 (2–52)	–0.12 (0.06)	0.026	0.049
EmCAB	15 (15–63)	11 (0–48)	10 (0–44)	–0.18 (0.05)	<0.001	<0.001
<b>Sullivan</b>						
SAS	40 (20–50)	40 (20–50)	30 (20–50)	–0.09 (0.05)	0.029	0.053
EmCAB	40 (20–60)	35 (0–60)	30 (0–55)	–0.15 (0.04)	<0.001	<0.001

CAD indicates coronary artery disease; EmCAB, Emory Cardiovascular Biobank; SAS, Southampton Atherosclerosis Study.

\*Adjusted for age and sex only.

†Adjusted for age, sex, smoking status, hypertension, and diabetes mellitus;  $\beta$  (SE) for the  $\ln+1$  transformed values.

**Table 5.** Association Between Genetic Variation at ADAMTS7 (rs3825807) and Incident Outcomes in the EmCAB Cohort

Events, No. (%)	ADAMTS7 Genotype			HR (95% CI)*	HR (95% CI)†
	AA	AG	GG		
All-cause mortality	73 (12.3)	116 (12.4)	43 (12.5)	1.12 (0.92–1.35)	1.13 (0.94–1.38)
Myocardial infarction	29 (4.9)	39 (4.2)	10 (3.0)	0.84 (0.60–1.17)	0.85 (0.61–1.18)
Revascularization	50 (8.4)	67 (7.2)	14 (4.2)	0.77 (0.60–0.98)	0.76 (0.59–0.98)

Hazard ratio (HR) and 95% confidence interval (CI) shown for the association between the G allele of rs3825807 and risk of incident events. EmCAB indicates Emory Cardiovascular Biobank.

\*Adjusted for age and sex only.

†Adjusted for age, sex, smoking status, hypertension, and diabetes mellitus.


In an analysis of the MESA (Multi-Ethnic Study of Atherosclerosis) cohort, an association was reported between a different SNP in ADAMTS7 and coronary artery calcification, but only in a Hispanic population subset, and no association was found with carotid intima-media thickness.<sup>19</sup> Similarly, ADAMTS7 was not associated with carotid intima-media thickness in Spanish patients with rheumatoid arthritis.<sup>20</sup> A positive association with CAD was, however, recently reported in a Chinese cohort using angiographic data, although the association was modest, used broad phenotypic definitions, was restricted to a Chinese population, and was not replicated in a smaller Portuguese study.<sup>21</sup>

## Study Strengths and Limitations

Our study builds on some of these reports and adds important novel data. First, using ex vivo plaque samples, we show that with each G allele there is a trend to lower intima-media thickness and other plaque characteristics indicative of atheroma development. Second, using clinical coronary angiographic data, we demonstrate that each copy of the G allele confers lower odds of having both obstructive disease and severe manifestations of CAD such as multivessel and proximal disease. This is also reflected with lower semiquantitative scores of CAD burden, a more refined and validated phenotype using Gensini and Sullivan scoring systems.<sup>12</sup>

We also confirmed that while ADAMTS7 variation was associated with CAD, it was not associated with MI per se, using the approach described by Reilly et al.<sup>2</sup> This has been used as evidence that ADAMTS7 confers risk through atherosclerosis and not by plaque rupture or thrombotic mechanisms, which may drive an MI. To further explore this hypothesis, we examined the association with incident outcomes and found that the protective G allele of the ADAMTS7 variant did not impact rates of all-cause death or MI. This is in line with a recent study of 1100 patients with known CAD, in whom no association was found with the same SNP and all-cause mortality over a median of 5 years, although there was an association with cardiovascular death ( $P=0.025$ ).<sup>22</sup> Intriguingly, in our study, where nonfatal events were also available, the rate of native vessel revascularization following enrollment was significantly lower in those carrying the protective allele, an indirect reflection of lower atheroma development and progression, and again supporting the concept that ADAMTS7 ordinarily drives progressive atherosclerosis.

Finally, a recent study reported that of the 45 loci known to associate with CAD risk, a variant at ADAMTS7 rs7178051, which is in modest linkage disequilibrium with rs3825807 (LD=0.52), exhibited an important gene-smoking interaction in 61 000 cases with coronary heart disease and 80 000 controls.<sup>4</sup> The protective effect of ADAMTS7 genetic



**Figure 2.** Association between genetic variation at ADAMTS7 (rs3825807) and incident revascularization events in the Emory Cardiovascular Biobank (EmCAB) cohort. Kaplan–Meier curve showing association between ADAMTS7 genotype and risk of incident native vessel revascularization (percutaneous or surgical coronary intervention), among participants within the EmCAB cohort. Genotype GG=blue; AG=green; AA=red.

variation on CAD risk was found to be lower in persons who smoked than in nonsmokers, while exposure of human coronary cell lines to cigarette smoke led to induction of ADAMTS7 activity. We examined this observation in our study and while there were some nonsignificant trends, we were unable to identify any significant interactions or differences in association between the rs3825807 SNP and CAD phenotypes among smokers and nonsmokers (Tables S1 through S3). However, it is worth noting that our study was within two cohorts *with* coronary heart disease, rather than a case-control design with coronary heart disease-free controls. Thus a much higher prevalence of smoking in our cohort (64.4% versus 56.9%) and smaller overall sample size (3981 versus 141 162) might have contributed to the lack of interactions with smoking found in the current study. Nonetheless, we believe our findings are complementary to the narrative emerging on the atherogenic role of ADAMTS7.

Our study is unique in that we were able to draw on several complementary sources of data and phenotypes related to atherosclerosis, overcoming limitations associated with each individually. Despite our consistent and promising findings, some limitations need to be considered. First, only a small number of ex vivo samples were available to study and these may have been prone to measurement error despite attempts to reduce potential variation with a priori measurement standard. Second, there is a degree of selection bias with both SAS and EmCAB cohorts enrolling only those undergoing coronary angiography and with CAD, which could have distorted genotype distribution. However, allele frequency was similar to those reported in general populations, suggesting that this was not likely to have been a major factor. Finally, the association with revascularization, while exciting and supportive of the overall hypothesis, should be interpreted with caution given these data were from a single center and revascularization as an end point is susceptible to clinical practice variation. However, together, our data provide consistent evidence for the role of ADAMTS7 in promoting atherosclerosis.

## Conclusions

Genetic variation at the *ADAMTS7* locus is associated with several complementary CAD phenotypes. Collectively, these findings support the emerging role of ADAMTS7 in promoting atherosclerosis and may represent a potential antiatherosclerosis drug target.

## Sources of Funding

Dr Patel is supported by a BHF intermediate fellowship award (FS14/76/30933).

## Disclosures

None.

## References

1. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, Stirrups K, König IR, Cazier JB, Johansson A, Hall AS, Lee JY, Willer CJ, Chambers JC, Esko T, Folkersen L, Goel A, Grundberg E, Havulinna AS, Ho WK, Hopewell JC, Eriksson N, Kleber ME, Kristiansson K, Lundmark P, Lytikainen LP, Rafelt S, Shungin D, Strawbridge RJ, Thorleifsson G, Tikkanen E, Van Zuydam N, Voight BF, Waite LL, Zhang W, Ziegler A, Absher D, Altshuler D, Balmforth AJ, Barroso I, Braund PS, Burgdorf C, Claudi-Boehm S, Cox D, Dimitriou M, Do R, Doney AS, El Mokhtari N, Eriksson P, Fischer K, Fontanillas P, Franco-Cereceda A, Gigante B, Groop L, Gustafsson S, Hager J, Hallmans G, Han BG, Hunt SE, Kang HM, Illig T, Kessler T, Knowles JW, Kolovou G, Kuusisto J, Langenberg C, Langford C, Leander K, Lokki ML, Lundmark A, McCarthy MI, Meisinger O, Mihailov E, Maouche S, Morris AD, Muller-Nurasyid M, Nikus K, Peden JF, Rayner NW, Rasheed A, Rosinger S, Rubin D, Rumpf MP, Schafer A, Sivananthan M, Song C, Stewart AF, Tan ST, Thorgeirsson G, van der Schoot CE, Wagner PJ, Wells GA, Wild PS, Yang TP, Amouyel P, Arveiler D, Basart H, Boehnke M, Boerwinkle E, Brambilla P, Cambien F, Cupples AL, de Faire U, Dehghan A, Diemert P, Epstein SE, Evans A, Ferrario MM, Ferrières J, Gauguier D, Go AS, Goodall AH, Gudnason V, Hazen SL, Holm H, Iribarren C, Jang Y, Kahonen M, Kee F, Kim HS, Klopp N, Koenig W, Kratzer W, Kuulasmaa K, Laakso M, Laaksonen R, Lind L, Ouweland WH, Parish S, Park JE, Fokhiresan S, Peters A, Quertermous T, Rader DJ, Salomaa V, Schadt E, Shah SH, Sinisalo J, Stark K, Stefansson K, Tregouet DA, Virtamo J, Wallentin L, Wareham N, Zimmermann ME, Nieminens MS, Hengstenberg C, Sandhu MS, Pastinen T, Syvanen AC, Hovingh GK, Dedoussis G, Franks PW, Lehtimäki T, Metspalu A, Zalloua PA, Siegbahn A, Schreiber S, Ripatti S, Blankenberg SS, Perola M, Clarke R, Boehm BO, O'Donnell C, Reilly MP, Marz W, Collins R, Kathiresan S, Hamsten A, Kooner JS, Thorsteinsdottir U, Danesh J, Palmer CN, Roberts R, Watkins H, Schunkert H, Samani NJ. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet.* 2013;45:25–33.
2. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader DJ. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. *Lancet.* 2011;377:383–392.
3. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardisino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boehnke M, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buyschaert I, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Ou L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeier J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoop JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Wittman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouweland WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* 2011;43:333–338.
4. Saleheen D, Zhao W, Young R, Nelson CP, Ho W, Ferguson JF, Rasheed A, Ou K, Nurnberg ST, Bauer RC, Goel A, Do R, Stewart AFR, Hartiala J, Zhang W, Thorleifsson G, Strawbridge RJ, Sinisalo J, Kanoni S, Sedaghat S, Marouli E, Kristiansson K, Hua Zhao J, Scott R, Gauguier D, Shah SH, Smith AV, van Zuydam N, Cox AJ, Willenborg C, Kessler T, Zeng L, Province MA, Ganna A, Lind L, Pedersen NL, White CC, Joensuu A, Edi Kleber M, Hall AS, Marz W, Salomaa V, O'Donnell C, Ingelsson E, Feitosa MF, Erdmann J, Bowden DW, Palmer CNA,



- Gudnason V, Faire U, Zalloua P, Wareham N, Thompson JR, Kuulasmaa K, Dedoussis G, Perola M, Dehghan A, Chambers JC, Koener J, Allayee H, Deloukas P, McPherson R, Stefansson K, Schunkert H, Kathiresan S, Farrall M, Marcel Frossard P, Rader DJ, Samani NJ, Reilly MP. Loss of cardioprotective effects at the ADAMTS7 locus as a result of gene-smoking interactions. *Circulation*. 2017;135:2336–2353.
5. Somerville RP, Longpre JM, Apel ED, Lewis RM, Wang LW, Sanes JR, Leduc R, Apte SS. ADAMTS7B, the full-length product of the ADAMTS7 gene, is a chondroitin sulfate proteoglycan containing a mucin domain. *J Biol Chem*. 2004;279:35159–35175.
  6. Pu X, Xiao Q, Kiechl S, Chan K, Ng FL, Gor S, Poston RN, Fang C, Patel A, Senver EC, Shaw-Hawkins S, Willeit J, Liu C, Zhu J, Tucker AT, Xu Q, Caulfield MJ, Ye S. ADAMTS7 cleavage and vascular smooth muscle cell migration is affected by a coronary-artery-disease-associated variant. *Am J Hum Genet*. 2013;92:366–374.
  7. Wang L, Zheng J, Bai X, Liu B, Liu CJ, Xu Q, Zhu Y, Wang N, Kong W, Wang X. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. *Circ Res*. 2009;104:688–698.
  8. Bauer RC, Tohyama J, Cui J, Cheng L, Yang J, Zhang X, Ou K, Paschos GK, Zheng XL, Parmacek MS, Rader DJ, Reilly MP. Knockout of ADAMTS7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice. *Circulation*. 2015;131:1202–1213.
  9. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation*. 1995;92:1355–1374.
  10. Ye S, Dunleavy L, Bannister W, Day LB, Tapper W, Collins AR, Day IN, Simpson I, Southampton Atherosclerosis S. Independent effects of the -219 G>T and epsilon 2/epsilon 3/epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study. *Eur J Hum Genet*. 2003;11:437–443.
  11. Ye S, Willeit J, Kronenberg F, Xu Q, Kiechl S. Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. *J Am Coll Cardiol*. 2008;52:378–384.
  12. Patel RS, Su S, Neeland IJ, Ahuja A, Veledar E, Zhao J, Helgadottir A, Holm H, Gulcher JR, Stefansson K, Waddy S, Vaccarino V, Zafari AM, Quyyumi AA. The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. *Eur Heart J*. 2010;31:3017–3023.
  13. Neeland IJ, Patel RS, Eshtehardi P, Dhawan S, McDaniel MC, Rab ST, Vaccarino V, Zafari AM, Samady H, Quyyumi AA. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. *Am Heart J*. 2012;164:547–552.e541.
  14. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A Jr, Russell RO Jr, Ryan TJ, Smith SC Jr. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on coronary angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. *Circulation*. 1999;99:2345–2357.
  15. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. *Am J Cardiol*. 1983;51:606.
  16. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. *Am Heart J*. 1990;119:1262–1267.
  17. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko YA, Veledar E, Samady H, Zafari AM, Sperling L, Vaccarino V, Jones DP, Quyyumi AA. Novel biomarker of oxidative stress is associated with risk of death in patients with coronary artery disease. *Circulation*. 2016;133:361–369.
  18. Kessler T, Zhang L, Liu Z, Yin X, Huang Y, Wang Y, Fu Y, Mayr M, Ge Q, Xu Q, Zhu Y, Wang X, Schmidt K, de Wit C, Erdmann J, Schunkert H, Aherrahrou Z, Kong W. ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling via cleavage of thrombospondin-1. *Circulation*. 2015;131:1191–1201.
  19. Vargas JD, Manichaikul A, Wang XQ, Rich SS, Rotter JJ, Post WS, Polak JF, Budoff MJ, Bluemke DA. Common genetic variants and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2016;245:230–236.
  20. Lopez-Mejias R, Genre F, Garcia-Bermudez M, Ubilla B, Castaneda S, Llorca J, Gonzalez-Juanatey C, Corrales A, Miranda-Filloo JA, Pina T, Gomez-Vaquero C, Rodriguez-Rodriguez L, Fernandez-Gutierrez B, Balsa A, Pascual-Salcedo D, Lopez-Longo FJ, Carreira P, Blanco R, Martin J, Gonzalez-Gay MA. Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis. *Mediators Inflamm*. 2014;2014:756279.
  21. You L, Tan L, Liu L, Shen R, Chaugai S, Wang DW, Cui W. ADAMTS7 locus confers high cross-race risk for development of coronary atheromatous plaque. *Mol Genet Genomics*. 2016;291:121–128.
  22. Pereira A, Palma Dos Reis R, Rodrigues R, Sousa AC, Gomes S, Borges S, Ornelas I, Freitas AI, Guerra G, Henriques E, Rodrigues M, Freitas S, Freitas C, Brehm A, Pereira D, Mendonca ML. Association of ADAMTS7 gene polymorphism with cardiovascular survival in coronary artery disease. *Physiol Genomics*. 2016;48:810–815.



## Genetic Variation at the *ADAMTS7* Locus is Associated With Reduced Severity of Coronary Artery Disease

Kenneth Chan, Xiangyuan Pu, Pratik Sandesara, Robin N. Poston, Iain A. Simpson, Arshed A. Quyyumi, Shu Ye and Riyaz S. Patel

*J Am Heart Assoc.* 2017;6:e006928; originally published October 31, 2017;

doi: 10.1161/JAHA.117.006928

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231  
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://jaha.ahajournals.org/content/6/11/e006928>